National Academy of Agricultural Sciences (NAAS)
|
PRINT ISSN : 2319-7692
Online ISSN : 2319-7706 Issues : 12 per year Publisher : Excellent Publishers Email : editorijcmas@gmail.com / submit@ijcmas.com Editor-in-chief: Dr.M.Prakash Index Copernicus ICV 2018: 95.39 NAAS RATING 2020: 5.38 |
In drug resistant tuberculosis (DRTB), Rifampicin resistance has always been prioritized hence Cartridge Based Nucleic Acid Amplification Test (CBNAAT) is recommended. However, since it doesn’t detect isoniazid resistance, rifampicin sensitive patients with unknown isoniazid status may be erroneously treated as drug sensitive TB leading to poor treatment outcomes and emergence of multidrug resistant (MDR) TB. Hence this study was undertaken to estimate the prevalence of isoniazid monoresistant TB and to find out the level of isoniazid resistance using Line probe assay (LPA). A total of 3227 consecutive sputum samples of patients between July 2023 and December 2023 were enrolled for the study. The samples were subjected to smear microscopy, CBNAAT and LPA (Line Probe Assay) and the results were documented. In our study the prevalence of isoniazid monoresistance was estimated to be 8.2%. Among isoniazid monoresistance the prevalence of high level resistance was 65.7% and that of low level resistance was 31.5%. This shows that isoniazid monoresistance forms a major chunk of DRTB, with majority of patients having high level resistance to isoniazid. Thus, LPA serves as a rapid diagnostic tool especially for the detection of isoniazid monoresistance.
Aber V R, Allen B W, Mitchison D A, Ayuma P, Edwards E A, Keyes A B. Laboratory studies on isolated positive cultures and the efficiency of direct smear examination. Tubercle. 1980 Sep 1;61(3):123-33. https://doi.org/10.1016/0041-3879(80)90001-x
Chowdhury K, Ahmad R, Sinha S, Dutta S, Haque M. Multidrug-Resistant TB (MDR-TB) and Extensively Drug-Resistant TB (XDR-TB) Among Children: Where We Stand Now. Cureus. 2023 Feb 18;15(2). https://doi.org/10.7759/cureus.35154
D'souza D T, Mistry N F, Vira T S, Dholakia Y, Hoffner S, Pasvol G, Nicol M, Wilkinson R J. High levels of multidrug resistant tuberculosis in new and treatment-failure patients from the Revised National Tuberculosis Control Programme in an urban metropolis (Mumbai) in Western India. BMC Public Health. 2009 Dec;9(1):1-9. https://doi.org/10.1186/1471-2458-9-211
Global Tuberculosis Report 2022 by World Health Organization. Journal of Diagnostics Concepts & Practice.
India tuberculosis annual report 2022.
Sharma S, Madan M, Agrawal C, Asthana A K. Genotype MTBDR plus assay for molecular detection of rifampicin and isoniazid resistance in Mycobacterium tuberculosis. Indian Journal of Pathology and Microbiology. 2014 Jul 1;57(3):423-6. https://doi.org/10.4103/0377-4929.138738
World Health Organization. Fluorescent light-emitting diode (LED) microscopy for diagnosis of tuberculosis: policy statement. World Health Organization; 2011.
World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008. World Health Organization; 2012.
World Health Organization. The global plan to stop TB 2011-2015: transforming the fight towards elimination of tuberculosis.
Yacoob F L, Philomina Jose B, Karunakaran Lelitha S D, Sreenivasan S. Primary multidrug resistant tuberculosis and utility of line probe assay for its detection in smear-positive sputum samples in a tertiary care hospital in South India. Journal of Pathogens. 2016 Mar 23;2016. https://doi.org/10.1155/2016/6235618
Citations |
 |
 |
 |
 |
